USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Blood

• Publication date

  2017-07-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2016-12-758219PMID 28495793
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• USP7 is essential for maintaining Rad18 stability and DNA damage tolerance

  2016cited by this paper
• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Expression of USP7 and MARCH7 Is Correlated with Poor Prognosis in Epithelial Ovarian Cancer.

  2016cited by this paper
• Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

  2016cited by this paper
• Approaches to modernize the combination drug development paradigm

  2016cited by this paper
• Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

  2016cited by this paper
• Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia

  2016cited by this paper
• Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia

  2016cited by this paper
• ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

  2016cited by this paper
• Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

  2016cited by this paper
• Minimal residual disease is an independent predictor for 10-year survival in CLL.

  2016cited by this paper
• DNA double-strand break repair: a tale of pathway choices.

  2016cited by this paper
• Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

  2016cited by this paper
• Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

  2015cited by this paper
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

  2015cited by this paper
• Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

  2015cited by this paper
• Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

  2015cited by this paper
• Ubiquitin‐specific protease 7 accelerates p14ARF degradation by deubiquitinating thyroid hormone receptor‐interacting protein 12 and promotes hepatocellular carcinoma progression

  2015cited by this paper
• Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants

  2015cited by this paper
• USP7 deubiquitinase promotes ubiquitin-dependent DNA damage signaling by stabilizing RNF168*

  2015cited by this paper
• Unravelling mechanisms of p53-mediated tumour suppression

  2014cited by this paper
• Homologous recombination maintenance of genome integrity during DNA damage tolerance

  2014cited by this paper
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

  2014cited by this paper
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

  2014cited by this paper
• Ubiquitin-specific Protease 7 Regulates Nucleotide Excision Repair through Deubiquitinating XPC Protein and Preventing XPC Protein from Undergoing Ultraviolet Light-induced and VCP/p97 Protein-regulated Proteolysis*

  2014cited by this paper
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• Deubiquitylating Enzymes and DNA Damage Response Pathways

  2013cited by this paper
• IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.

  2013cited by this paper
• Expression of HAUSP in gliomas correlates with disease progression and survival of patients

  2013cited by this paper
• The ATM protein kinase: regulating the cellular response to genotoxic stress, and more

  2013cited by this paper
• Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

  2013cited by this paper
• Poly(ADP-ribose) signaling in cell death.

  2013cited by this paper
• Requirement of Rad18 protein for replication through DNA lesions in mouse and human cells

  2012cited by this paper
• Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47.

  2012cited by this paper
• Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

  2012cited by this paper
• Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme.

  2012cited by this paper
• Deubiquitination of NF-κB by Ubiquitin-Specific Protease-7 promotes transcription

  2012cited by this paper
• A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

  2012cited by this paper
• UV-sensitive syndrome protein UVSSA recruits USP7 to regulate transcription-coupled repair

  2012cited by this paper
• The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• RAD18 transmits DNA damage signaling to elicit homologous recombination repair

  2009cited by this paper
• Parthanatos, a messenger of death.

  2009cited by this paper
• Clinical Trials and Observations

  2008cited by this paper
• The deubiquitinylation and localization of PTEN are regulated by a HAUSP–PML network

  2008cited by this paper
• Clinical significance of TP53 mutation in myeloma

  2007cited by this paper
• Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

  2007cited by this paper
• Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

  2005cited by this paper
• A dynamic role of HAUSP in the p53-Mdm2 pathway.

  2004cited by this paper
• HAUSP is Required for p53 Destabilization

  2004cited by this paper
• Tumour suppression: Disruption of HAUSP gene stabilizes p53

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Enhanced Genomic Instability and Defective Postreplication Repair in RAD18 Knockout Mouse Embryonic Stem Cells

  2003cited by this paper
• ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.

  2002cited by this paper
• Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization

  2002cited by this paper
• DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.

  2001cited by this paper
• Genomic aberrations and survival in chronic lymphocytic leukemia.

  2000cited by this paper
• P53 Binding Protein 1 (53bp1) Is an Early Participant in the Cellular Response to DNA Double-Strand Breaks

  2000cited by this paper
• DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis

  1999cited by this paper
• Molecular characterization of mitochondrial apoptosis-inducing factor

  1999cited by this paper
• XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.

  1999cited by this paper
• Inactivation of the ATM gene in T-cell prolymphocytic leukemias.

  1998cited by this paper
• Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.

  1996cited by this paper
• p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy.

  1993cited by this paper
• The single cell gel electrophoresis assay (comet assay): a European review.

  1993cited by this paper
• Testing of known carcinogens and noncarcinogens in the Syrian hamster embryo (SHE) micronucleus test in vitro; correlations with in vivo micronucleus formation and cell transformation.

  1993cited by this paper
• Pharmacokinetics of mitomycin-C in plasma and tumor tissue of cervical cancer patients and in selected tissues of female rats.

  1986cited by this paper

• NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL

  2025cites this paper
• Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities

  2025cites this paper
• Antitumor Activity of USP7 Inhibitor GNE-6776 in Non-Small Cell Lung Cancer Involves Regulation of Epithelial-Mesenchymal Transition, Cell Cycle, Wnt/β-Catenin, and PI3K/AKT/mTOR Pathways

  2025cites this paper
• USP7 deubiquitinase stabilizes FAN1 to support DNA crosslink repair and suppress CAG repeat expansion

  2025cites this paper
• USP7 Deregulation Impairs S Phase Specific DNA Repair after Irradiation in Breast Cancer Cells

  2024cites this paper
• Virtual screening of natural products targeting ubiquitin-specific protease 7

  2024cites this paper
• Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy.

  2024cites this paper
• USP15 regulates radiation-induced DNA damage and intestinal injury through K48-linked deubiquitination and stabilisation of ATM

  2024cites this paper
• Ubiquitin-specific proteases (USPs) in leukemia: a systematic review

  2024cites this paper
• Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options

  2024cites this paper
• Integrated network findings reveal ubiquitin-specific protease 44 overexpression suppresses tumorigenicity of liver cancer

  2023cites this paper
• USP7 reduces the level of nuclear DICER, impairing DNA damage response and promoting cancer progression

  2023cites this paper
• Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment

  2023cites this paper
• RNA methylation, homologous recombination repair and therapeutic resistance.

  2023cites this paper
• Ubiquitin specific peptidase 47 contributes to liver regeneration.

  2023cites this paper
• USP15-USP7 Axis and UBE2T Differential Expression May Predict Pathogenesis and Poor Prognosis in De Novo Myelodysplastic Neoplasm

  2023cites this paper
• EBNA1 Upregulates P53-Inhibiting Genes in Burkitt's Lymphoma Cell Line.

  2023cites this paper
• USP25 inhibits DNA damage by stabilizing BARD1 protein in a house dust mite‐induced asthmatic model in vitro and in vivo

  2022cites this paper
• USP7 Inhibitors in Cancer Immunotherapy: Current Status and Perspective

  2022cites this paper
• USP7 substrates identified by proteomics analysis reveal the specificity of USP7

  2022cites this paper
• USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma

  2022cites this paper
• Highlights in USP7 inhibitors for cancer treatment

  2022cites this paper
• Compartmentalized regulation of NAD+ by Di (2-ethyl-hexyl) phthalate induces DNA damage in placental trophoblast

  2022cites this paper
• Discovery of a Potent and Selective Degrader for USP7.

  2022cites this paper
• IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma

  2022cites this paper
• USP8 inhibitor–induced DNA damage activates cell cycle arrest, apoptosis, and autophagy in esophageal squamous cell carcinoma

  2022cites this paper
• A review on the treatment of multiple myeloma with small molecular agents in the past five years.

  2021cites this paper
• Ubiquitin‐specific protease 7 as a potential therapeutic target in dogs with hematopoietic malignancies

  2021cites this paper
• Proteome Analysis of USP7 Substrates Revealed Its Role in Melanoma Through PI3K/Akt/FOXO and AMPK Pathways

  2021cites this paper
• Targeting Ubiquitin-Specific Protease 7 (USP7) in Cancer: A New Insight to Overcome Drug Resistance

  2021cites this paper
• Deubiquitinases: Modulators of Different Types of Regulated Cell Death

  2021influential citation
• Novel fluorescent-based reporter cell line engineered for monitoring homologous recombination events

  2021cites this paper
• Restraining CDK1–cyclin B activation: PP2A on the cUSP(7)

  2021cites this paper
• The USP7-TRIM27 axis mediates non-canonical PRC1.1 function and is a druggable target in leukemia

  2021cites this paper
• Deubiquitinases in hematological malignancies

  2021cites this paper
• Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives

  2021influential citation
• Aniline-containing derivatives of parthenolide: Synthesis and anti-chronic lymphocytic leukaemia activity

  2020cites this paper
• Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets

  2020cites this paper
• USP7 inhibition inhibits proliferation and induces megakaryocytic differentiation in MDS cells by upregulating gelsolin

  2020cites this paper
• Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth

  2020cites this paper
• Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo

  2020cites this paper
• USP7 Is a Master Regulator of Genome Stability

  2020cites this paper
• USP7 regulates melanoma progression through PI3K/Akt/FOXO and AMPK Pathways

  2020cites this paper
• The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options

  2020cites this paper
• ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer.

  2020cites this paper
• USP7, negatively regulated by miR‐409‐5p, aggravates hypoxia‐induced cardiomyocyte injury

  2020cites this paper
• The Role of Deubiquitinating Enzymes in Hematopoiesis and Hematological Malignancies

  2020cites this paper
• Biology and Treatment of Hairy Cell Leukemia

  2020cites this paper
• Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Anti-Tumor Activity.

  2020cites this paper
• Ubiquitin-Specific-Processing Protease 7 Regulates Female Germline Stem Cell Self-Renewal Through DNA Methylation

  2020cites this paper
• The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors

  2019cites this paper
• Fonctions et régulations de la kinase CHK1 dans l'hématopoïèse normale et leucémique

  2019cites this paper
• USP7 as part of non-canonical PRC1.1 is a druggable target in leukemia

  2019cites this paper
• Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia

  2019cites this paper
• Beyond reversal: ubiquitin and ubiquitin-like proteases and the orchestration of the DNA double strand break repair response

  2019cites this paper
• USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis

  2019cites this paper
• DNA methylation modifier LSH inhibits p53 ubiquitination and transactivates p53 to promote lipid metabolism

  2019cites this paper
• Functional analysis of deubiquitylating enzymes in tumorigenesis and development.

  2019cites this paper
• Low‐dose vemurafenib in hairy cell leukemia patients with active infection

  2019cites this paper
• Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease.

  2019cites this paper
• USP39 regulates the cell cycle, survival, and growth of human leukemia cells

  2019cites this paper
• Light-Trigerred Cellular Epigenetic Molecule Release To Reverse Tumor Multidrug Resistance.

  2018cites this paper
• Targeting ubiquitin specific protease 7 in cancer: A deubiquitinase with great prospects

  2018cites this paper
• Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases

  2018cites this paper
• Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF‐κB signaling pathway in multiple myeloma

  2018cites this paper
• Targeting the overexpressed USP7 inhibits esophageal squamous cell carcinoma cell growth by inducing NOXA‐mediated apoptosis

  2018cites this paper
• Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma

  2018cites this paper
• Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis

  2018cites this paper
• Identification of USP7 as an essential component to maintain integrity and function of non-canonical PRC1.1 in leukemia

  2018cites this paper
• Targeting deubiquitinases in CLL.

  2017cites this paper